Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on developing treatments for liver disease and obesity, has been garnering attention ...

although further clinical studies are needed to fully understand their efficacy and mechanisms of action in humans. Glucagon-like peptide-1 (GLP-1): A hormone that helps regulate blood sugar ...

Dr. Kaestner added, "This research uncovers a critical mechanism that helps ... increasing insulin levels or insulin action, without directly targeting glucagon. Inhibition of G6PC2 is different ...

COYA 303 is an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 ... COYA 303 exhibited a dual immunomodulatory mechanism of action resulting in an additive ...